Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab. / Rohrberg, Kristoffer Staal; Pappot, Helle; Lassen, Ulrik; Westman, Maj; Olesen, René K; Pfeiffer, Per; Ladekarl, Morten; Mau-Sørensen, Paul Morten; Christensen, Ib J; Skov, Birgit G.

In: Cancer Biology & Therapy, Vol. 11, No. 8, 04.2011, p. 732-9.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Rohrberg, KS, Pappot, H, Lassen, U, Westman, M, Olesen, RK, Pfeiffer, P, Ladekarl, M, Mau-Sørensen, PM, Christensen, IJ & Skov, BG 2011, 'Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab', Cancer Biology & Therapy, vol. 11, no. 8, pp. 732-9. <http://www.landesbioscience.com/journals/cbt/article/14889/>

APA

Rohrberg, K. S., Pappot, H., Lassen, U., Westman, M., Olesen, R. K., Pfeiffer, P., Ladekarl, M., Mau-Sørensen, P. M., Christensen, I. J., & Skov, B. G. (2011). Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab. Cancer Biology & Therapy, 11(8), 732-9. http://www.landesbioscience.com/journals/cbt/article/14889/

Vancouver

Rohrberg KS, Pappot H, Lassen U, Westman M, Olesen RK, Pfeiffer P et al. Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab. Cancer Biology & Therapy. 2011 Apr;11(8):732-9.

Author

Rohrberg, Kristoffer Staal ; Pappot, Helle ; Lassen, Ulrik ; Westman, Maj ; Olesen, René K ; Pfeiffer, Per ; Ladekarl, Morten ; Mau-Sørensen, Paul Morten ; Christensen, Ib J ; Skov, Birgit G. / Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab. In: Cancer Biology & Therapy. 2011 ; Vol. 11, No. 8. pp. 732-9.

Bibtex

@article{567546ca2006480e8b859f78bb29eae5,
title = "Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab",
abstract = "Malignancies in the upper gastrointestinal (UGI) tract are amongst the most aggressive cancers and only few treatment options exist. We have recently analysed data from a phase II trial where patients with UGI cancers were treated with erlotinib and bevacizumab. The combination therapy could not be recommended in an unselected population of patients with chemo-refractory UGI cancer. However, a subpopulation of patients did benefit from the therapy. In this prospectively planned biomarker study we investigated vascular endothelial growth factor A (VEGF-A), VEGF receptor 2 (VEGFR-2) and epidermal growth factor receptor (EGFR) by immunohistochemistry and KRAS mutation status detected by PCR as potential predictors of effect of therapy. High VEGF-A expression was correlated to longer overall survival (HR: 0.8, 95%CI: 0.7-0.9) and high VEGFR-2 expression to shorter progression free survival (HR: 1.4, 95%CI: 1.0-1.9). EGFR expression and KRAS mutation status were not correlated to response or survival. We conclude that VEGF-A and VEGFR-2 could potentially be predictive markers in patients with UGI cancers treated with erlotinib and bevacizumab.",
author = "Rohrberg, {Kristoffer Staal} and Helle Pappot and Ulrik Lassen and Maj Westman and Olesen, {Ren{\'e} K} and Per Pfeiffer and Morten Ladekarl and Mau-S{\o}rensen, {Paul Morten} and Christensen, {Ib J} and Skov, {Birgit G}",
year = "2011",
month = apr,
language = "English",
volume = "11",
pages = "732--9",
journal = "Cancer Biology & Therapy",
issn = "1538-4047",
publisher = "Taylor & Francis",
number = "8",

}

RIS

TY - JOUR

T1 - Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab

AU - Rohrberg, Kristoffer Staal

AU - Pappot, Helle

AU - Lassen, Ulrik

AU - Westman, Maj

AU - Olesen, René K

AU - Pfeiffer, Per

AU - Ladekarl, Morten

AU - Mau-Sørensen, Paul Morten

AU - Christensen, Ib J

AU - Skov, Birgit G

PY - 2011/4

Y1 - 2011/4

N2 - Malignancies in the upper gastrointestinal (UGI) tract are amongst the most aggressive cancers and only few treatment options exist. We have recently analysed data from a phase II trial where patients with UGI cancers were treated with erlotinib and bevacizumab. The combination therapy could not be recommended in an unselected population of patients with chemo-refractory UGI cancer. However, a subpopulation of patients did benefit from the therapy. In this prospectively planned biomarker study we investigated vascular endothelial growth factor A (VEGF-A), VEGF receptor 2 (VEGFR-2) and epidermal growth factor receptor (EGFR) by immunohistochemistry and KRAS mutation status detected by PCR as potential predictors of effect of therapy. High VEGF-A expression was correlated to longer overall survival (HR: 0.8, 95%CI: 0.7-0.9) and high VEGFR-2 expression to shorter progression free survival (HR: 1.4, 95%CI: 1.0-1.9). EGFR expression and KRAS mutation status were not correlated to response or survival. We conclude that VEGF-A and VEGFR-2 could potentially be predictive markers in patients with UGI cancers treated with erlotinib and bevacizumab.

AB - Malignancies in the upper gastrointestinal (UGI) tract are amongst the most aggressive cancers and only few treatment options exist. We have recently analysed data from a phase II trial where patients with UGI cancers were treated with erlotinib and bevacizumab. The combination therapy could not be recommended in an unselected population of patients with chemo-refractory UGI cancer. However, a subpopulation of patients did benefit from the therapy. In this prospectively planned biomarker study we investigated vascular endothelial growth factor A (VEGF-A), VEGF receptor 2 (VEGFR-2) and epidermal growth factor receptor (EGFR) by immunohistochemistry and KRAS mutation status detected by PCR as potential predictors of effect of therapy. High VEGF-A expression was correlated to longer overall survival (HR: 0.8, 95%CI: 0.7-0.9) and high VEGFR-2 expression to shorter progression free survival (HR: 1.4, 95%CI: 1.0-1.9). EGFR expression and KRAS mutation status were not correlated to response or survival. We conclude that VEGF-A and VEGFR-2 could potentially be predictive markers in patients with UGI cancers treated with erlotinib and bevacizumab.

M3 - Journal article

VL - 11

SP - 732

EP - 739

JO - Cancer Biology & Therapy

JF - Cancer Biology & Therapy

SN - 1538-4047

IS - 8

ER -

ID: 40195150